Hello!

Our ambulatory infusion center has been dealing with frequent episodes of throat irritation in patients receiving ocrelizumab infusions. This is typically mild, however, can result in delays in care that can be up to several hours (to allow for pausing the infusion, potentially administering medications, restarting the infusion at a slower rate, titrating up, etc).

Have any of your sites that administer ocrelizumab developed any standardized ways of managing mild-moderate infusion reactions? Would you be willing to share your experience?

Thank you!
Francesca Mernick
Massachusetts General Hospital